INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback